Skip to content
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Saturday, December 6, 2025
World Today News
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
Copyright 2021 - All Right Reserved
Home ยป Wegovy
Tag:

Wegovy

Health

TikTok trend to health trap: Doctors sound alarm on dark side of using diabetes drugs Ozempic, Mounjaro for weight loss |

by Dr. Michael Lee โ€“ Health Editor October 28, 2025
written by Dr. Michael Lee โ€“ Health Editor

TikTok Trend to โฃHealth Trap:โข Doctors Warn of Risks in Off-label Diabetes Drug Use forโค Weight โ€ŒLoss

October 28, 2025, โ€‹08:11:12 AM โ€‹EST โ€Œ – A viral TikTok trendโค promoting theโค use of diabetes medications Ozempic โ€Œand Mounjaro for rapid weight loss is prompting urgent warningsโ€ from medical professionals, who cite potentially serious health consequences stemming from off-label โ€prescriptions and self-medication. โคThe surgeโ€‹ in demand,fueled by social mediaโข endorsements,is creating shortages forโฃ patients wihtโฃ diabetes and raising concerns about the long-term effects of these drugs whenโ€ used by individuals without a medical need.

Originally designed to manage type โ€2 diabetesโ€ by regulating blood sugar, โ€‹semaglutide (Ozempic) and tirzepatide (Mounjaro) have gained notoriety forโ€ their appetite-suppressing side effects, โฃleading to significantโ€‹ weight loss in some users. While the FDA has approved semaglutideโ€Œ under the brand name Wegovy specifically for weightโ€Œ management in individualsโ€ with โขobesityโ€‹ or weight-related medical conditions, itsโค use โฃfor cosmetic weight loss-particularly without medical supervision-is driving a perilous trend. Doctors report a growing numberโข of patientsโฃ experiencing severe nausea, โขvomiting, diarrhea, and,โ€‹ in rare cases, pancreatitis andโ€‹ intestinal blockages. โ€‹

The American Society โขof Metabolic and Bariatric Surgery (ASMBS) estimates โ€Œthatโค demand โฃfor these medications has increased by over โ€‹300% in recent months, largely attributed to social โ€‹media influence. “We’re seeing a significant diversion of theseโ€Œ medications, โขwith people obtaining them through questionable sources โขor pressuring doctors to prescribe them off-label,” โ€Œstated Dr.Amanda Velazquez, โฃPresident of ASMBS, in a recent press conference. โ€Œ”This isn’tโฃ a harmless shortcut to weight loss; it’s aโข potentiallyโ€Œ dangerous gamble with your โ€‹health.”

The medications work by mimicking a natural hormone that regulates appetite andโ€ blood sugar, but their long-term effects on individuals without diabetes are largely unknown. Experts caution that prolonged use can lead โ€to nutrient deficiencies, muscle loss, and potentially even cardiovascular problems. Furthermore, the suddenโ€‹ discontinuation of these drugs can result in rapid weight regain and other adverse effects.

Authorities โคare โ€investigatingโฃ reports of โ€Œcompounded versions โ€‹of semaglutide and tirzepatideโ€‹ circulatingโ€‹ online, which may contain incorrect โคdosages or harmful โ€impurities. โขThe FDA has issued โ€warnings against purchasing medicationsโ€‹ from unregulated sourcesโ€‹ and โฃurges individuals to consult with a healthcare professional โขbeforeโฃ considering any โคweight loss drug.Theโ€ situation is evolving, โ€Œwith ongoing research aimed at better understanding the risks and โคbenefits ofโ€ these medications, and increased scrutiny of online platforms promoting their off-label use.

October 28, 2025 0 comments
0 FacebookTwitterPinterestEmail
World

Novo, Lilly Weight Loss Drugs: New Guidelines Recommend First-Line Treatment

by Priya Shah โ€“ Business Editor October 2, 2025
written by Priya Shah โ€“ Business Editor

New Guidelines Recommend GLP-1 Medications for Targeted Obesity Complications

Recent guidelines are shaping how โคobesity and its related healthโข issues are treated, with a focus on utilizing medications like semaglutide and tirzepatide – drugs belonging to the GLP-1 agonist โขclass – in aโฃ more targeted manner. Dr.Andreea ciudin of Vall d’Hebronโค University Hospital in Barcelona, a co-author of the โฃguidelines, emphasized that while these recommendations areโค valuable, they shouldn’t replace a doctor’sโ€‹ comprehensive clinical judgment.

The guidelines, developed after analyzing clinical trial data on weight loss, safety, โ€‹and effectiveness in the presence of specificโค complications, suggest specific drugs โขas first-line โ€‹treatments for particular conditions.โข For patients โ€‹suffering from obstructive sleep apnea due to excess โขadipose tissue, tirzepatide is recommended. Semaglutide is suggested forโ€ those experiencing knee osteoarthritis.

Beyond addressingโ€‹ the physical consequences of obesity, the guidelines also offerโข recommendations for โ€Œconditionsโ€ linked to metabolic and โฃimmune dysfunction. Semaglutide is favored for โ€individuals with a history of heart disease or stroke. Tirzepatide is recommendedโฃ for those with non-alcoholic fatty liverโ€‹ disease, while either tirzepatide or semaglutide can be usedโ€‹ for patients with prediabetes or type 2 โ€diabetes. It’s crucial โ€Œto note that these drugs were originally developed โขto manage โคtype 2 diabetes.

The authors acknowledge the high cost of these medications and stress that the long-term costs of not treating obesity – allowing itโ€Œ to progress and cause organ damage – should be equally considered in healthcare decisions.

The guidelines also highlight that obesity managementโฃ should extend beyond weight loss andโ€Œ complication treatment, encompassing improvementsโ€ in mental well-being,โค physical fitness, social functioning, and overall quality of life. While many newer medications haven’t been specifically tested for individual complications, โฃthe observed weight loss โขhas consistently correlated with improvements โ€Œin various health issues. Researchers believe these drugs may positively impact conditions like chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, โขcertain cancers,โค and mental health conditions.

Professorโ€ Volkan Yumuk, President of the European โฃAssociation for the Study of Obesity (EASO), stated โ€the institution plans to regularly update the treatment algorithm to reflect the rapidly โคevolving research in obesity medications.

However, โฃother organizations caution thatโข medication alone isn’t enough. โฃ The American College of Lifestyle Medicine, the American Society for Nutrition, the โ€ŒObesity Medicine Association,โฃ and The โฃobesity Society jointly advised in June that GLP-1 treatment โ€Œ must be combinedโ€ with nutritional and โขlifestyle interventions. โ€ŒThey point to potentialโ€Œ challenges with GLP-1s, including gastrointestinal side effects, nutrient โฃdeficiencies, muscle and bone โ€‹loss, high โ€Œcosts, discontinuation, and weight regain, highlighting the need for a holistic approach.

October 2, 2025 0 comments
0 FacebookTwitterPinterestEmail
Health

Ozempic & Weight Loss: A Journey with Rising Costs

by Dr. Michael Lee โ€“ Health Editor September 24, 2025
written by Dr. Michael Lee โ€“ Health Editor

Insurance Coverageโ€Œ Lapse Leaves Woman Facing Weight Regain After Ozempic Success

WAUSAU, WI – A wisconsinโค woman, identified as Bobbi, experienced โ€Œsignificant weight loss with the GLP-1 medication Ozempic, only to see her insurance โ€Œcoverage discontinued,โข leading to a return to her previous weight โ€and concerns about unregulated alternatives.

Bobbi’s insurance โ€Œprovider, TeamCare, declined โ€Œto commentโ€ on the reason for the coverage change.However, a TeamCare employee reportedly stated the company stopped covering medications used solely for weight loss approximately a year ago.

“So I wasโ€‹ desperate.โ€Œ I was looking onโ€ the black โ€Œmarketโ€‹ for anythingโข similar to it. โ€I was actuallyโ€Œ looking to โฃsee if anybodyโ€‹ was selling their Ozempic,” Bobbi โ€Œtold NewsChannel7.

unableโ€Œ to afford Ozempic throughโ€‹ conventional channels, Bobbi turned to a third-party weight loss drug, which was three times cheaper. Dr. Davis warned that these medicationsโข are โ€”not technically FDA โ€regulated,”โ€Œ and concerns exist regarding proper manufacturing,dosage,and absorption.

“Soโ€Œ we don’t โ€‹always know without a doubtโค that the medications are being made properly, โ€that they’reโค at the correct โฃdose, that they’re being prescribed in โฃa way that isโ€ going toโ€Œ beโข absorbed correctly,” Dr. Davis explained.

Bobbi reported โ€the third-party drug was ineffective,โฃ causing vomiting and providing no noticeable โฃphysical changes. She also received an incorrect dosage andโ€‹ lacked follow-up care from providers. She โ€Œhas been โฃoff all weight โขloss drugs as April 2024.

Bobbi โฃhad successfully โ€reduced herโค clothing sizeโฃ from an 18 to a 10 while on Ozempic, but has as returned to a size 18. “I just wanted to do โฃit โ€‹for me. So I’dโ€Œ have a better โฃquality of โฃlife, lose โ€‹weight, gainโ€ confidence-and that’s all โขgone again,”โ€ sheโค said. โข”It’s like the golden ticket. it really is.”

The case highlights โ€Œgrowing concerns about access โ€Œto GLP-1โค medications, โฃinitially โ€Œdevelopedโ€‹ for diabetes management but increasingly prescribed for weight loss, and the potential risks associated with seekingโ€‹ unregulated โฃalternatives.

Copyright 2025 WSAW. All rights reserved.

September 24, 2025 0 comments
0 FacebookTwitterPinterestEmail
World

Novo Nordisk Job Cuts: Company Restructures to Rival Eli Lilly

by Priya Shah โ€“ Business Editor September 10, 2025
written by Priya Shah โ€“ Business Editor

Novo Nordisk, the maker โ€Œof theโ€‹ blockbuster weight-loss drug Wegovy, โ€Œannounced Wednesday โ€Œit will cut โ€Œ9,000 jobsโฃ – roughly 16% of its global workforce – in โ€a restructuring effort โขaimed at โขsaving 8 billion Danish crowns ($1.26 billion) annually. The move comesโ€Œ as theโค companyโ€‹ faces increased competition from U.S.โค rival Eli Lilly and navigates challenges from copycat versionsโ€‹ of Wegovy.”Novo nordisk today announced a company-wide transformation โ€‹to simplify its organisation, improveโ€Œ the speed of decision-making, and reallocate resources โขtowardsโฃ the company’s โ€‹growth opportunities in diabetes and obesity,” the company saeid in a โคstatement.

The โ€restructuring followsโข a global hiring freeze โคimplemented in August,which covered all non-critical roles. Novo โขNordiskโ€Œ has experiencedโ€Œ significant demand for its diabetes and obesityโ€Œ treatments, but is concurrently working โ€Œto defend its market โ€position โฃagainst emerging competitors. The company did not specify where the job cuts would be concentrated.

September 10, 2025 0 comments
0 FacebookTwitterPinterestEmail
Business

Danish Ozempic maker Novo Nordisk in Crisis, slimming pill has to turn tide

by Priya Shah โ€“ Business Editor August 23, 2025
written by Priya Shah โ€“ Business Editor

“`html

A T-shirt in a street in Amsterdam. Ozempic has become a โฃcultural phenomenon in a short โ€‹time
August 23, 2025 0 comments
0 FacebookTwitterPinterestEmail
News

a new set of tariffs, and a company in Kinsale โ€“ The Irish Times

by Emma Walker โ€“ News Editor July 28, 2025
written by Emma Walker โ€“ News Editor

Ireland Sides with Big Pharma in EU Regulatory Debate, Preserving Drug Patent Protections

DUBLIN – Ireland has shifted its stance in a crucial European Union debate, ultimately aligning with major pharmaceutical companies to maintain existing patent protections for new medicines. The decision, which saw Ireland join a coalition of “pro-innovation” countries, effectively blocks proposed EU regulations that would have reduced the period of regulatory data protection for new drugs.

The pharmaceutical industry had lobbied intensely against the proposed changes,arguing that a reduction in patent protection would stifle innovation and economic competitiveness in Europe. In a letter dated March 7th, pfizer informed a senior adviser to EU industry commissioner Stรฉphane Sรฉjournรฉ of an “urgent need” for Europe to enhance its economic competitiveness considering “recent geopolitical developments.”

Michaela Hagenhofer, head of Johnson & Johnson‘s Irish operations, communicated her opposition to the commission’s plan to cut regulatory protection for new medicines to Irish Minister for Enterprise Peter Burke on February 25th.She requested Ireland’s support in a coalition of countries opposing these changes at the EU level. Similarly, Samantha Humphreys, MSD’s Irish director, urged the government to maintain the “status quo” in a letter dated February 11th. These communications where made public following Freedom of Data Act requests.

However, internal records indicate that the Department of Health favored a “more balanced” approach, suggesting that some changes to the regulations were necessary, according to a March 18th briefing paper. Despite this internal divergence, Taoiseach Leo Varadkar ultimately sided with the industry’s position. Ireland’s revised stance meant joining countries that opposed diluting the “protection” afforded to companies for their newly developed drugs.

The outcome of this debate, settled in an EU vote earlier this year, resulted in national capitals agreeing to keep the eight-year window for regulatory data protection unchanged. A modified version of the new regulations is expected to be finalized in the coming months, marking a important victory for the pharmaceutical sector. This advancement comes as the industry faces the looming “patent cliff,” a period where a significant number of blockbuster drugs lose patent protection, potentially impacting revenues and driving the need for new innovations.

July 28, 2025 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Search:

Recent Posts

  • Title: Texas Tech Linebacker Jacob Rodriguez Wins Butkus Award

    December 6, 2025
  • Title: Modi-Putin Summit Yields Limited Deals Amid Western Pressure

    December 6, 2025
  • N.J. Weather Forecast: Cold Snap Coming After Weekend Warmth

    December 6, 2025
  • Thomas Mรผller & Lionel Messi: MLS Final Preview & Bayern Coach’s Prediction

    December 6, 2025
  • Juan Manuel Bordeu. Spectacular photos and the testimony of his family: his childhood, the golden years in motorsports and his loves

    December 6, 2025

Follow Me

Follow Me
  • Live News Feeds
  • Short Important News
  • Most Important News
  • Headlinez
  • Most Recommended Web Hosting
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Copyright Notice
  • Disclaimer
  • DMCA Policy
  • EDITORIAL TEAM
  • Links
  • Privacy Policy
  • Terms & Conditions

@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com


Back To Top
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
World Today News
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Technology
  • World
@2025 - All Right Reserved.

Hosted by Byohosting – Most Recommended Web Hosting – for complains, abuse, advertising contact: contact@world-today-news.com